Rafferty Asset Management, LLC Cyma Bay Therapeutics, Inc. Transaction History

Rafferty Asset Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$12.63 - $24.47 $101,090 - $195,857	8,004 Added 76.78%	18,428 $435,000
Q3 2023 Nov 13, 2023	BUY	$10.86 - $17.62 $113,204 - $183,670	10,424 New	10,424 $155,000
Q2 2022 Aug 12, 2022	BUY	$1.72 - $3.39 $6,480 - $12,773	3,768 Added 15.67%	27,810 $82,000
Q1 2022 May 13, 2022	SELL	$2.77 - $3.64 $13,334 - $17,522	-4,814 Reduced 16.68%	24,042 $75,000
Q4 2021 Feb 10, 2022	BUY	$3.23 - $4.6 $6,808 - $9,696	2,108 Added 7.88%	28,856 $98,000
Q3 2021 Nov 10, 2021	BUY	$3.47 - $4.42 $92,815 - $118,226	26,748 New	26,748 $98,000
Q1 2021 May 10, 2021	SELL	$4.23 - $6.55 $72,168 - $111,749	-17,061 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$5.73 - $9.03 $32,701 - $51,534	5,707 Added 50.26%	17,061 $98,000
Q3 2020 Nov 13, 2020	BUY	$3.32 - $7.24 $37,695 - $82,202	11,354 New	11,354 $82,000
Q4 2019 Feb 10, 2020	SELL	$1.33 - $5.93 $17,782 - $79,284	-13,370 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$5.12 - $7.21 $68,454 - $96,397	13,370 New	13,370 $68,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.